Clinical Relevance of Small Airways Disease in Severe Asthma Patients Treated With Anti-InterLeukin-5 Therapy

Last updated: January 23, 2023
Sponsor: Medical Centre Leeuwarden
Overall Status: Active - Recruiting

Phase

N/A

Condition

Asthma

Treatment

N/A

Clinical Study ID

NCT05706597
SAIL2022
  • All Genders

Study Summary

The aim of this research is to investigate the extent and clinical relevance of small airways disease in severe eosinophilic asthma patients treated with anti-IL5/5R therapy.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Severe asthma patients treated with anti-IL5/5R therapy (i.e. mepolizumab,benralizumab, reslizumab) for at least 4 months.

Exclusion

Exclusion Criteria:

  • No information about lung function at baseline, or after both 4 months and 12 months.
  • No information about clinical response (i.e. number of exacerbations, reduction ofmOCS/ maintenance oral corticosteroid dose, ACQ, AQLQ) after both 4 months and 12months.
  • Treatment with another anti-IL5/5R therapy before

Study Design

Total Participants: 110
Study Start date:
December 02, 2022
Estimated Completion Date:
March 01, 2023

Connect with a study center

  • Medical Center Leeuwarden

    Leeuwarden,
    Netherlands

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.